Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
and identification of HLA-restricted epitopes derived from them As a successful candidate, you will: · Work with both genetically engineered mouse models, patient-derived AML xenograft models
-
Advanced written and verbal communication skills Proficient with technology, spreadsheet management skills, with the ability to analyze trends. Excellent organizational skills, ability to manage multiple
-
, shaping the future of medicine through cutting-edge research. The Department of Integrative Translational Sciences at City of Hope comprises a diverse team of biologists, data scientists, engineers
-
Mathematics, Statistics, Physics, Computer Science, Engineering or related discipline Experience with genome sequencing data (ex. DNA, RNA, ATAC seq) Experience with stochastic dynamical systems and probability
-
and identification of HLA-restricted epitopes derived from them As a successful candidate, you will: · Work with both genetically engineered mouse models, patient-derived AML xenograft models
-
. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and
-
-process and release testing of GMP Manufacturing and analytical development for cellular immunotherapy products. This is a fast-paced lab involved in cutting edge technology, research and clinical cellular
-
, including first-in-human studies with genetically engineered hematopoietic stem and progenitor cells (HSPC) and T cells. As a successful candidate, you will: · Conduct research on next-generation
-
experience) is available in the Cellular Therapy Production Center (CTPC). This is a fast-paced lab involved in cutting edge technology, research and clinical immunotherapeutic programs. New personnel will be
-
experience) is available in the Cellular Therapy Production Center (CTPC). This is a fast-paced lab involved in cutting edge technology, research and clinical immunotherapeutic programs. New personnel will